Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor rather than the GHRH receptor. It’s marketed on “selectivity,” the claim that it raises growth hormone without raising cortisol, ACTH, or prolactin, but that claim rests on a single 1998 study in pigs with no human counterpart. Its only two human efficacy trials, both for postoperative bowel recovery, either missed the primary endpoint or were never published. It is not approved for any use, and a 2024 FDA advisory committee voted unanimously against including it on the compounding list.
Ask about Ipamorelin
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Synthetic pentapeptide, ghrelin-receptor (growth hormone secretagogue) agonist |
| Primary research interest | Growth hormone release; postoperative gastrointestinal (bowel) recovery |
| Highest available evidence | Tier 1 for one published phase 2 trial (postoperative ileus, 117 patients, primary endpoint missed). A second, larger phase 2 trial (320 patients) was completed but never reported |
| Human research available | Limited. Two phase 2 efficacy trials exist, both intravenous and both for postoperative bowel recovery, plus a phase 1 study in healthy men |
| Development status | Discontinued clinical development; not advanced beyond these two trials |
| Regulatory status | Not FDA approved for any use; a 2024 FDA advisory committee voted unanimously against including it on the compounding list |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Ipamorelin |
| Alternative names | NNC 26-0161 |
| Peptide sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (C-terminal amide) |
| Amino-acid length | 5 (two non-proteinogenic residues: aminoisobutyric acid at position 1, 2-naphthylalanine at position 3) |
| Molecular formula | C38H49N9O5 |
| Molecular weight | ≈711.85 g/mol |
| CAS Registry Number | 170851-70-4 |
| PubChem CID | 9831659 |
| Peptide class | Ghrelin-receptor (GHSR-1a) agonist, growth hormone secretagogue |
| Primary biological target | Ghrelin receptor (GHSR-1a), not the GHRH receptor |
| Developer / originator | Novo Nordisk (originally developed by Novo Nordisk research) |
| Development status | Not an approved pharmaceutical; research chemical / vendor product only |
What it is
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys with a C-terminal amide. Two of its five residues are not standard amino acids: aminoisobutyric acid at position one and 2-naphthylalanine at position three. FDA counts those two non-proteinogenic residues as part of why the substance is difficult to characterise.
It is a growth hormone secretagogue, meaning it acts at the ghrelin receptor rather than the GHRH receptor, which is what separates it from sermorelin, tesamorelin and CJC-1295. In the originating work its growth hormone release was blocked by GHRP antagonists and not by a GHRH antagonist, which is how that was established before the receptor was cloned.
It was discovered at Novo Nordisk as NNC 26-0161 and published in 1998 as the first selective growth hormone secretagogue.
How it works, and what the selectivity claim rests on
Ipamorelin agonises the growth hormone secretagogue receptor 1a. In rat pituitary cells its half-maximal effect came at 1.3 nanomolar with a maximum response of 85 percent, against GHRP-6 at 2.2 nanomolar and 100 percent. In conscious swine its half-maximal dose was 2.3 nanomoles per kilogram, against GHRP-6 at 3.9 and GHRP-2 at 0.6.
Read that last figure again. GHRP-2 is more potent than ipamorelin. The compound was never sold on potency. It is sold on selectivity, meaning the claim that it raises growth hormone without raising cortisol, prolactin or ACTH.
That claim rests on one experiment, in pigs, published in 1998. Intravenous dosing in conscious swine, with FSH, LH, prolactin, TSH, ACTH and cortisol measured. None of the secretagogues tested affected FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 both raised ACTH and cortisol. Ipamorelin did not, and the authors noted the absence held even at doses more than 200 times the growth hormone half-maximal dose.
That is a real, well-designed result. It is also a pig result, and there is no human counterpart. The only published human pharmacology study measured ipamorelin concentrations and growth hormone, and nothing else. There is no published human cortisol, ACTH or prolactin dataset for this compound at any dose by any route. FDA put it plainly: there are insufficient data to conclude that ipamorelin would not raise safety concerns similar to those associated with approved products that stimulate growth hormone release.
One piece of internal evidence does support the selectivity being structurally real rather than an artefact. Novo Nordisk derived a successor compound from ipamorelin, tabimorelin, and that one did raise cortisol, by about 50 percent at every dose tested in the same species.
Potential benefits and research applications
Postoperative gastrointestinal recovery
What is being investigated: whether stimulating GH release speeds bowel-function recovery after abdominal surgery. How the effect might occur: proposed motility effects via the ghrelin-receptor pathway, independent of the GH axis. Evidence: two registered human phase 2 trials exist. Strength: weak to inconclusive, the published trial (Beck 2014, NCT00672074, n=117) found a numerical difference favoring ipamorelin (25.3 vs. 32.6 hours to tolerating a solid meal) that did not reach statistical significance (p=0.15), and explicitly reported no significant difference on any key or secondary endpoint. A larger, three-times-bigger follow-up dose-finding trial (NCT01280344, n=320) completed in 2013 and has never posted results or been published, the single largest gap in the public record for this compound. Limitation: “has not been established” is the accurate framing; no ipamorelin trial has ever met its efficacy endpoint in a human being.
Growth hormone deficiency (unsupported)
What is being investigated: nothing, currently, this indication has never been tested. Evidence: none. FDA states directly that it has not identified data to support effectiveness for growth hormone deficiency in children or adults. Strength: none established. This is the sharpest gap between what ipamorelin is popularly discussed for and what has actually been studied.
Raising IGF-1 (unsupported)
No human IGF-1 value for ipamorelin exists, from any study, at any dose, by any route. In a 15-day rat dosing study, total IGF-1 did not change. This widely repeated claim has no human source at all.
Figures in this table summarize amounts and routes reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use | Route | Amount reported | Frequency | Evidence category |
|---|---|---|---|---|
| Postoperative bowel recovery (human trials) | Intravenous | 0.03 to 0.06 mg/kg per dose | Per-dose, trial-specific | Published human clinical trial (one missed its endpoint; the other never published full results) |
| General use, as commonly circulated online | Subcutaneous (never studied in humans by this route) | 200 to 300 mcg | Two to three times daily | Community / vendor reported, roughly a tenth of the studied IV amount, extrapolated to an untested route |
Research evidence
Three human datasets, and that is all
The phase 1 study, from 1999, gave 15 minute intravenous infusions at five ascending doses to healthy men. Terminal half-life about two hours, clearance 0.078 litres per hour per kilogram. Growth hormone rose in a single episode peaking at 40 minutes and returning to negligible by six hours at every dose. Inter-individual variability was larger for the response than for the pharmacokinetics.
Two things that study did not report: IGF-1 and cortisol. No human IGF-1 value for ipamorelin exists, from that study or any other, at any dose, by any route. The near-universal claim that ipamorelin raises IGF-1 has no human source. In rats, fifteen days of dosing did not change total IGF-1.
Then two phase 2 trials, both in postoperative ileus, both intravenous.
The trial that reported: endpoint missed
NCT00672074 ran from 2008 to 2009 across nineteen US sites, 117 patients, 0.03 milligrams per kilogram intravenously twice daily from the first postoperative day for up to seven days. The primary endpoint was time from first dose to tolerating a standardised solid meal.
Median 25.3 hours on ipamorelin against 32.6 on placebo. A difference of 7.3 hours at p equals 0.15. The authors wrote that there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses. No difference in time to bowel movement, readiness for discharge or length of stay. A subgroup of patients having open laparotomy showed shorter recovery, which was exploratory rather than pre-specified.
It was published in 2014, five years after completion.
On safety, treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm and 94.8 percent of placebo. FDA Category 2 listing states that a study published in the literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. The advisory committee transcript adds the necessary qualifier: those events occurred after completion of therapy, and it is unclear whether the deaths were related to ipamorelin because causality was not provided in the article. Per-arm death counts are not public. Both halves of that belong together.
The trial that never reported, and it was the big one
NCT01280344 ran from 2011 to 2014 across 45 US sites with 320 patients, nearly three times the size of the published trial. Randomised, quadruple-blind, placebo-controlled, dose-finding, with three dose levels: 0.03 milligrams per kilogram twice daily, 0.06 twice daily and 0.06 three times daily, up to triple the daily dose of the earlier trial. It was restricted to open resections with incisions of at least ten centimetres, which is to say it was designed to test whether the open-laparotomy subgroup signal was real.
Primary completion was June 2013. No results have been posted and no publication exists.
That is the single biggest hole in the public record on this compound. Whether the higher doses worked where the lower one did not is unknown, and whether the subgroup signal held is unknown, because the trial designed to answer both questions has never released its data.
How the programme ended
Novo Nordisk discovered ipamorelin and then used it as a starting point to improve on. Within the same publication series the company produced a series of more orally available analogues and moved to tabimorelin, which entered phase 2. Ipamorelin, an injectable, was the abandoned parent of an oral programme.
It was picked up again for postoperative ileus, ran the two trials above, and stopped. Development-tracking databases record its growth-disorder status as discontinued and its gastrointestinal status as no development reported. The company that owned it took a different asset through phase 3 instead.
Two sentences are defensible from that record and both are worth stating. No ipamorelin trial has ever met an efficacy endpoint in a human being. And growth hormone deficiency, the indication ipamorelin is most associated with in consumer writing, was never tested in a single registered trial. FDA states that it has not identified data to support effectiveness for the diagnosis or treatment of growth hormone deficiency in children or adults.
Safety
The longest human exposure ever studied is seven days, by intravenous infusion, in patients recovering from bowel surgery. There is nothing beyond about a week.
There is no human pharmacokinetic data by the subcutaneous route, which is the route essentially everyone uses. FDA found none in any population. Every published human figure comes from a 15 minute intravenous infusion, so bioavailability, peak concentration and growth hormone response after a subcutaneous injection are unmeasured in people.
On toxicology the record is empty: no acute toxicity study, no repeat-dose toxicity, no genotoxicity, no carcinogenicity, and no reproductive or developmental work specific to ipamorelin. Human glucose and insulin sensitivity have never been measured, and tachyphylaxis has never been tested in a human at any duration.
FDA also found the substance not well characterised physically and chemically, noting that the certificates of analysis it reviewed lacked specifications for aggregates, bacterial endotoxins and bioburden, and that the unnatural amino acids add to the difficulty.
Regulatory status
Not approved for any indication in any country, and it has no pharmacopoeial monograph.
The compounding history is more decisive than for most compounds on this site, and it is frequently reported wrongly. Ipamorelin acetate was nominated for the 503A bulk drug substances list and the nomination was withdrawn. FDA then set it for advisory committee evaluation, and on 29 October 2024 the Pharmacy Compounding Advisory Committee voted on it. The vote was zero in favour, twelve against, one abstention, for the free base, and identically for the acetate. Unanimous against, twice.
FDA grounds were that the substance is not well characterised, that there was insufficient information to determine how long it had been used in compounding, that no effectiveness data exists for growth hormone deficiency or for postoperative ileus, and that approved alternatives exist for both.
Separately, ipamorelin acetate remains in Category 2 under the 503B interim policy. FDA’s 503B categories list (last updated March 21, 2025, read October 8, 2026) and its safety-risk page (current as of April 22, 2026) both show it there, which is a live designation rather than a withdrawn one. It does not appear on FDA’s 503A categories list (updated May 14, 2026) because its Category 2 listing applies to 503B outsourcing facilities only. Several secondary sources collapse these into a single claim that it was removed from Category 2. For ipamorelin that is wrong.
It was not among the substances considered at the July 2026 advisory committee meeting.
WADA names ipamorelin directly in section S2.2.4, among growth hormone secretagogues and their mimetics. Prohibited at all times, in and out of competition, and Sport Integrity Australia states that a therapeutic use exemption would not be granted.
Frequently asked questions
What is ipamorelin?
A synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor.
Is ipamorelin FDA approved?
No. An FDA advisory committee voted unanimously (12-0-1) against including it on the compounding list in October 2024.
What dosage has been studied?
All human doses were intravenous: 0.03 to 0.06 mg/kg per dose in the two ileus trials. No subcutaneous human dose has ever been studied.
What dosage commonly circulates online?
200 to 300 mcg subcutaneously, two to three times daily, roughly a tenth of the studied intravenous amount, by an untested route.
Has it been studied in humans?
Yes, three datasets: one PK study and two ileus trials. One ileus trial missed its endpoint; the larger one never reported.
Does it raise IGF-1?
No human data exists showing this. The claim has no human source.
Is the “no cortisol” claim proven in humans?
No, it comes from one 1998 pig study only.
What side effects have been reported?
Limited data (7 days maximum exposure); a published report of serious events including death exists but causality to ipamorelin was not established.
How strong is the evidence overall?
Weak-to-moderate for basic human pharmacokinetics; essentially absent for any efficacy claim, since the one published efficacy trial was negative.
What remains unknown?
Anything about subcutaneous use in humans, IGF-1 effects, long-term safety, and whether the 320-patient unpublished trial found anything different.
Bottom line
Ipamorelin’s central marketing claim, that it raises growth hormone selectively, without the cortisol and ACTH spikes seen with older secretagogues, is genuinely interesting and has real mechanistic support, but that support is a single 1998 study in pigs, never replicated in a human being. Its own human efficacy record is a straight negative: the published phase 2 trial missed its primary endpoint, and the larger trial designed to settle the open question has sat unpublished for over a decade. No dose of ipamorelin has ever been given to a human subcutaneously in a study, which is the route essentially everyone uses. It is not approved anywhere, and the FDA’s compounding advisory committee voted unanimously against it in 2024.
Reported amounts and the evidence behind them: Ipamorelin dosage: what the trials and online protocols report.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General | Subcutaneous | 200 to 300 mcg | Two or three times daily | 8 to 12 weeks on, 4 to 6 off |
| With CJC-1295, as a blend | Subcutaneous | Varies by seller | Not standardised | 8 to 12 weeks |
| With tesamorelin, as a blend | Subcutaneous | A few hundred mcg | Once daily, morning | Not specified |
The convention is 200 to 300 micrograms subcutaneously, two or three times a day, timed on a stated rationale of mimicking natural growth hormone pulses, in eight to twelve week blocks. It is usually paired with the no-DAC form of CJC-1295.
Two comparisons are worth making because both cut against the usual pattern on this site.
The route is wrong relative to the evidence. Every human figure for ipamorelin comes from intravenous infusion, and there is no human subcutaneous pharmacokinetic data at all. So the circulating figures are not scaled-down versions of studied doses, they are doses by a route that has never been measured in a person.
And the amount is far lower than anything studied. The phase 2 trials used 0.03 to 0.06 milligrams per kilogram per dose, which for a 70 kilogram adult is 2.1 to 4.2 mg, against a circulating figure of 0.2 to 0.3 mg. So the market dose is roughly a tenth of the dose that failed to beat placebo, by a different route, for a different purpose.
The aggregate pattern above was formally surveyed and published in a 2026 review, which tabulated it alongside the peer-reviewed regimens and treated it explicitly as behavioural material rather than evidence. That review assigns ipamorelin an evidence tier reflecting phase 1 human data and the postoperative ileus programme, with no efficacy data in any growth-hormone-related metabolic indication.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. Preclinical. Original characterisation, and the source of the selectivity that distinguishes ipamorelin from GHRP-6 and hexarelin, which is the reason the GHRP-6 synergy literature cannot simply be assumed to transfer. PMID 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. Intravenous infusion; no IGF-1 or cortisol reported. PMID 10496658
- Beck DE, et al. Randomized proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29(12):1527-34. Human. Intravenous 0.03 mg/kg twice daily up to 7 days, 117 enrolled. Time to first tolerated meal 25.3 versus 32.6 hours, p = 0.15, not significant. The only published human trial of ipamorelin. PMID 25331030
- Helsinn Therapeutics. Safety and efficacy of ipamorelin on recovery of gastrointestinal function. Phase 2, 320 patients, 45 sites, completed 2014. No results posted, no publication. NCT01280344
- US Food and Drug Administration. Ipamorelin (free base) and ipamorelin acetate. Briefing document for the Pharmacy Compounding Advisory Committee meeting of 29 October 2024. FDA Briefing Document-4
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee minutes, 29 October 2024. Ipamorelin free base 0 yes, 12 no, 1 abstain. Ipamorelin acetate 0 yes, 12 no, 1 abstain. FDA media 185412
- US Food and Drug Administration. Ipamorelin acetate, 503B, listed 29 September 2023, citing immunogenicity risk and serious adverse events including death reported in the literature after intravenous administration. FDA Category 2
- Fifteen days of ipamorelin dosing in rats: bone growth outcomes, unchanged total IGF-1, and a marginal reduction in growth hormone response to a provocative dose. J Endocrinol. 1999. PMID 10373343
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Front Endocrinol 2026;17:1822475. Review. States that the half life of CJC-1295 without DAC is not reported in human studies, that the combination with ipamorelin is largely driven by anecdotal rationale, and that no human trials of the combination exist. PMID 42395176
- World Anti-Doping Agency. Prohibited List, section S2.2.4, GHRH and its analogues, naming CJC-1293, CJC-1295, sermorelin and tesamorelin. Prohibited at all times. WADA S2.2.4
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
| Trial | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus NCT00672074 | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 117 | Dec 2009 | Apr 14, 2017 |
| Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function NCT01280344 | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 320 | Jun 2013 | Apr 13, 2017 |
Compare Ipamorelin with related compounds
Research area: Growth hormone axis.